Videos

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

National Cancer Institute expert, Christopher J. Melani, MD, discusses the synergy of 5 drugs that make up a targeted therapy regimen for patients with mantle cell lymphoma.

Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.

Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.

Practical perspectives on the optimal use of combination lenvatinib-pembrolizumab in endometrial cancer.

Insight on the combination of lenvatinib and pembrolizumab in endometrial cancer, investigated between the KEYNOTE-146 and KEYNOTE-775 trials.

Brian Slomovitz, MD, MS, FACOG, provides a brief review of endometrial cancer relapse and corresponding therapeutic approaches.

Expert perspectives on the endometrial cancer treatment landscape in light of approved therapies and drug classes.

Mark Roschewski, MD, discusses how different large cell lymphoma subtypes may respond to different therapies.

Alice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.

Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.

Leora Horn, MD, discusses the importance of the Impower133 trial.

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses the DUO-E trial, which evaluated durvalumab, a PD-L1 inhibitor, with or without olaparib in patients with endometrial cancer, design, and end points.

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Katherine Poruk, MD, discusses upcoming surgical advances being made the field of pancreatic cancer.

Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Shifting their focus to the REFLECT trial of lenvatinib in unresectable hepatocellular carcinoma, panelists consider use of tyrosine kinase inhibition in this setting.

A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.

Theodore W. Laetsch, MD, discusses which trials were used for the retrospective study of the TRK inhibitor larotrectinib for the treatment of TRK-fusion cancers, including thyroid cancers.

A brief discussion on the potential role for adjuvant therapy in patients with hepatocellular carcinoma.

Taking recent clinical trial data into account, panelists consider the best treatment option for a patient with metastatic hepatocellular carcinoma.

In the context of metastatic hepatocellular carcinoma, panelists reflect on the value of multidisciplinary care at their institutions.

After introducing the third case, a patient with metastatic hepatocellular carcinoma, experts share their perspectives on the optimal diagnosis and work-up of advanced disease.

Tycel Phillips, MD, a clinical associate professor of hematology and medical oncology at the University of Michigan Health, discusses the mechanism of action of glofitamab in patients with mantle cell lymphoma.

Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.